- Home
- ENTA vs WNEB Comparison
ENTA vs WNEB Comparison
Compare ENTA & WNEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- WNEB
- Stock Information
- Founded
- ENTA 1995
- WNEB 1853
- Country
- ENTA United States
- WNEB United States
- Employees
- ENTA N/A
- WNEB N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- WNEB Savings Institutions
- Sector
- ENTA Health Care
- WNEB Finance
- Exchange
- ENTA Nasdaq
- WNEB Nasdaq
- Market Cap
- ENTA 164.6M
- WNEB 195.7M
- IPO Year
- ENTA 2013
- WNEB N/A
- Fundamental
- Price
- ENTA $8.28
- WNEB $12.20
- Analyst Decision
- ENTA Strong Buy
- WNEB Buy
- Analyst Count
- ENTA 4
- WNEB 2
- Target Price
- ENTA $22.25
- WNEB $11.00
- AVG Volume (30 Days)
- ENTA 158.9K
- WNEB 68.7K
- Earning Date
- ENTA 08-11-2025
- WNEB 10-22-2025
- Dividend Yield
- ENTA N/A
- WNEB 2.31%
- EPS Growth
- ENTA N/A
- WNEB N/A
- EPS
- ENTA N/A
- WNEB 0.59
- Revenue
- ENTA $64,806,000.00
- WNEB $76,036,000.00
- Revenue This Year
- ENTA N/A
- WNEB N/A
- Revenue Next Year
- ENTA $1.65
- WNEB $7.36
- P/E Ratio
- ENTA N/A
- WNEB $20.64
- Revenue Growth
- ENTA N/A
- WNEB 2.15
- 52 Week Low
- ENTA $4.09
- WNEB $7.63
- 52 Week High
- ENTA $13.37
- WNEB $12.70
- Technical
- Relative Strength Index (RSI)
- ENTA 49.11
- WNEB 58.37
- Support Level
- ENTA $8.25
- WNEB $12.02
- Resistance Level
- ENTA $9.08
- WNEB $12.70
- Average True Range (ATR)
- ENTA 0.44
- WNEB 0.21
- MACD
- ENTA -0.08
- WNEB -0.10
- Stochastic Oscillator
- ENTA 3.78
- WNEB 26.47
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About WNEB Western New England Bancorp Inc.
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.